	porporaity.	
All rights reserved.	. No reuse allowed without permission.	
·		

1	Microbial genes outperform species and SNVs as diagnostic markers
2	for Crohn's disease on multicohort fecal metagenomes empowered by
3	artificial intelligence
4	
5	Sheng Gao ^{1,#} , Xiang Gao ^{1,#} , Ruixin Zhu ^{1,*} , Dingfeng Wu ² , Zhongsheng Feng ¹ , Na Jiao ² , Ruicong
6	Sun ¹ , Wenxing Gao ¹ , Qing He ^{3,*} , Zhanju Liu ^{4,*} , Lixin Zhu ^{5,*}
7	
8	1 Department of Gastroenterology, The Shanghai Tenth People's Hospital, School of Medicine,
9	School of Life Sciences and Technology, Tongji University, Shanghai 200072, P. R. China.
10	2 National Clinical Research Center for Child Health, the Children's Hospital, Zhejiang University
11	School of Medicine, Hangzhou 310058, Zhejiang, P. R. China.
12	3 Departments of Gastroenterology and Nutrition, the Sixth Affiliated Hospital, Sun Yat-sen
13	University, Guangzhou 510655, P.R. China.
14	4 Center for IBD Research, Department of Gastroenterology, The Shanghai Tenth People's
15	Hospital, School of Medicine, Tongji University, Shanghai 200072, P. R. China.
16	5 Department of Colorectal Surgery, Guangdong Institute of Gastroenterology, Guangdong
17	Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital,
18	Sun Yat-sen University, Guangzhou 510655, P.R. China.
19	

20 [#]Co-first authors.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

²¹

22 ***Corresponding authors:**

- 23 Lixin Zhu (zhulx6@mail.sysu.edu.cn)
- 24 Department of Colorectal Surgery, Guangdong Institute of Gastroenterology, Guangdong
- 25 Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital,
- 26 Sun Yat-sen University, Guangzhou 510655, P.R. China.
- 27 Tel: 86-199-4625-6235
- 28
- 29 Zhanju Liu (liuzhanju88@126.com)
- 30 Center for IBD Research, Department of Gastroenterology, The Shanghai Tenth People's Hospital,
- 31 School of Medicine, Tongji University, Shanghai 200072, P. R. China.
- 32 Tel: 86-21-6630-1164
- 33
- 34 Qing He (heqing5@mail.sysu.edu.cn)
- 35 Departments of Gastroenterology and Nutrition, the Sixth Affiliated Hospital, Sun Yat-sen
- 36 University, Guangzhou 510655, P.R. China.
- 37 Tel: 86-136-0906-1002
- 38
- 39 Ruixin Zhu (rxzhu@tongji.edu.cn)
- 40 Department of Gastroenterology, The Shanghai Tenth People's Hospital, School of Medicine,
- 41 School of Life Sciences and Technology, Tongji University, Shanghai 200072, P. R. China.
- 42 Tel: 86-21-6598-1041

43 Abstract

44	Background: Dysbiosis of gut microbial community is associated with the pathogenesis of CD and
45	may serve as a promising non-invasive diagnostic tool. We aimed to compare the performances of
46	the microbial markers of different biological levels by conducting a multidimensional analysis on
47	the microbial metagenomes of CD.
48	
49	Methods: We collected fecal metagenomic datasets generated from eight cohorts that altogether
50	include 870 CD patients and 548 healthy controls. The microbial alterations in CD patients were
51	assessed at multidimensional levels including species-, gene- and SNV- level, and then diagnostic
52	models were constructed using artificial intelligence algorithm.
53	
54	Results: A total of 227 species, 1047 microbial genes and 21877 microbial SNVs were identified
55	that differed between CD and controls. The species-, gene- and SNV- models achieved an average
56	AUC of 0.97, 0.95 and 0.77, respectively. Notably, the gene model exhibited superior diagnostic
57	capability, achieving average AUCs of 0.89 and 0.91 in internal and external validations,
58	respectively. Moreover, the gene model was specific for CD against other microbiome-related
59	diseases. Further, we found that phosphotransferase system (PTS) contributed substantially to the
60	diagnostic capability of the gene model. The outstanding performance of PTS was mainly explained
61	by genes <i>celB</i> and <i>manY</i> , which demonstrated high predictabilities for CD with the metagenomic

62 datasets and was validated in an independent cohort by qRT-PCR analysis.

64	Conclusions: Our global metagenomic analysis unravels the multidimensional alterations of the
65	microbial communities in CD, and identifies microbial genes as robust diagnostic biomarkers across
66	geographically and culturally distinct cohorts.
67	
68	Keywords: Crohn's disease, microbiome biomarkers, non-invasive diagnosis, artificial intelligence,
69	phosphotransferase system
70	
71	Introduction
72	Crohn's disease (CD), one of the two main forms of inflammatory bowel disease (IBD), is
73	characterized by skip lesions and transmural inflammation of the gastrointestinal tract. The
74	incidence of CD has risen globally in past two decades, causing substantial economic burdens for
75	patients and societies [1, 2]. Currently diagnosis of CD is mainly based on the combined evaluation
76	of endoscopic, radiographic and pathological findings [3, 4]. However, the diagnostic power of
77	endoscopy is often limited by patient compliance, bowel preparation quality and other
78	uncontrollable factors [5]. Therefore, a sensitive, specific and convenient non-invasive diagnostic
79	tool for CD is urgently needed.
80	
81	Serologic and fecal biomarkers, such as C-reactive protein and fecal calprotectin, have been used
82	as indicators to evaluate inflammatory activity in IBD [6, 7]. However, the accuracy and specificity
83	of these biomarkers are not satisfactory. Recently, the diagnostic potential of the microbial

84 signatures has emerged as potential diagnostic markers for IBD [8-12]. For instance, Pascal et al.

85	constructed a diagnostic model using microbial species abundance and achieved a sensitivity of
86	81.8% for CD [11]. Similarly, Franzosa et al. reported a model that achieved an area under the ROC
87	curve (AUC) of 0.92 [12]. Along this line, future effort is needed to conduct similar analysis
88	incorporating multiple cohorts of distinct cultural and geographical background to identify markers
89	of universal value.

90

91 Notably, species abundance may not be an accurate representative of the microbial functions as 92 reflected by the fact that the nomenclatures of many gut microbial species are currently and 93 constantly being adjusted. In this regard, the diagnostic value of microbial genes and their 94 polymorphisms has become popular subjects of investigation [13-16] (Fig. 1B). For example, 95 microbial functional genes outperformed microbial species in distinguishing CRC from controls 96 [14]. Similarly, a recent study demonstrated high accuracy of microbial SNVs for diagnosing CD 97 [17]. Currently, an integrated investigation on multidimensional signatures of CD at species-, gene-98 and SNV-levels is missing and seems to be warranted in the clinic.

In this study, with large numbers of whole metagenome sequencing (WMS) samples from multiple cohorts, we constructed diagnostic models for CD and systematically assessed the predictabilities of multidimensional signatures. Candidate biomarkers for CD diagnosis were identified and further validated by qRT-PCR with an independent cohort. Collectively, these results uncover the multidimensional alterations of the microbial communities in CD patients and provide unbiased and robust biomarkers for CD diagnosis.

107	Methods
108	Study inclusion and data acquisition
109	For discovery dataset, we used PubMed to search for studies that published fecal shotgun
110	metagenomic data of CD patients and controls. Raw FASTQ files of 1241 fecal samples from four
111	studies were downloaded from the European Nucleotide Archive (ENA) including datasets 'D1-D4'
112	(Fig. 1A).
113	
114	For validation dataset, the raw data of 177 samples from three studies were collected from the
115	ENA including datasets 'V1-V3' (Fig. 1A). The clinical characteristics of patients were shown in
116	Table S1.
117	
118	To evaluate whether the prediction model is specific for CD rather than non-CD diseases, we
119	further collected five cohorts of non-CD diseases including ulcerative colitis (UC), colorectal cancer
120	(CRC), type-2 diabetes (T2D), liver cirrhosis (LC) and Parkinson's disease (PD).
121	
122	Patient recruitment and sample collection of Chinese cohorts
123	The Chinese cohort D5 consisted of 40 CD and 53 control samples (Table S2). The CD patients
124	and controls were enrolled at the Sixth Affiliated Hospital of the Sun Yat-sen University,
125	Guangdong province, China.
126	

127	For qRT-PCR validation, we enrolled CD patients and controls at the Shanghai Tenth People's
128	Hospital. Patients with diagnosis of CD were included in the study. Potential participants were
129	excluded if they were pregnant, were diagnosed with indeterminate colitis, had an acute
130	gastrointestinal infection, or had antibiotic therapy within 3 months. In total, we collected 73 fecal
131	samples (N = 37 for CD and N = 36 for control, Table S3) that were then stored at -80 °C before
132	DNA extraction. The study was approved by the Institutional Review Board at the Shanghai Tenth
133	People's Hospital, Tongji University, Shanghai (No. 20KT863), and each participant provided
134	informed consent.
135	
136	Quality control of WMS sequencing data
137	For preprocessing of the WMS sequencing data, quality control was performed using KneadData
138	V0.6.0. Subsequently, reads with length lower than 50bp, or with low quality bases were filtered
139	out by Trimmomatic software (V0.32). Furthermore, reads that mapped to the mammalian genome,
140	bacterial plasmids, UNiVec sequences, and chimeric sequences were removed.
141	
142	Annotation and abundance estimation of microbial taxa, genes and SNVs
143	For multi-kingdom species level analysis, The customized reference database was constructed with
144	18756 bacterial, 359 archaeal, 9346 viral reference genomes from the NCBI Refseq database
145	(accessed on January 2020), and 1094 fungal reference genomes from the NCBI Refseq database,

- 146 FungiDB (http://fungidb.org) and Ensemble (http://fungi.ensembl.org) (all accessed on January
- 147 2020). Quality-filtered reads were aligned and quantified by Kraken2 [18] and Bracken, respectively.

148	For microbial gene level analysis, we assembled the quality-filtered metagenomes into contigs
149	with Megahit (v1.2.9) [19] using 'meta-sensitive' parameters. Contigs shorter than 500-bp were
150	excluded for further analysis. Prodigal (v2.6.3) software [20] was used to predict genes at the
151	metagenome mode (-p meta). A non-redundant microbial gene reference was constructed with CD-
152	HIT [21] using a sequence identity cut-off of 0.95, and a minimum coverage cut-off of 0.9 for the
153	shorter sequences. The reference was annotated with EggNOG mapper (v2.0.1) based on EggNOG
154	orthology data. Subsequently, CoverM (V4.0) was used to estimate gene abundances by mapping
155	reads to the non-redundant reference and to calculate the coverage of genes in the original contigs.
156	The abundance of KEGG orthologous (KOs) groups were calculated by summing the expression of
157	genes annotated to the same KOs.
158	For SNV level analysis, MIDAS was used to perform microbial SNV annotation [22]. A
159	customized reference genome database was constructed to include 7 species with sufficient
160	coverage (>3X) in at least 20% of all samples. Then, the WMS reads were mapped to the database
161	for SNV calling. Subsequently, the SNV profiles of all samples were merged, with only bi-allelic
162	positions chosen. Other parameters were identical with those of the preset option '-core_snps'
163	(merge_midas.py snps -core_snps).
164	
165	Diagnostic model construction and evaluation

166 *Model construction*

167 Artificial intelligence (AI) algorithm called feedforward neural network (FNN) was employed to

168 construct the diagnostic model. In detail, the hidden layers were activated by rectified linear unit

169	(ReLU) activation function and the output layer was activated by sigmoid function. Subsequently,
170	we performed stratified ten-fold cross-validation to avoid overfitting issue and model estimation
171	using Scikit-learn 1.1.0. Finally, we trained the diagnostic model with well-optimized
172	hyperparameter combinations with TensorFlow 2.8.0. The feature importance was evaluated with
173	SHapley Additive exPlanations (SHAP) [23] to explain the output of machine learning model.
174	
175	Model interpretation
176	To better interpret the compositions and corresponding contributions of features in model, we
177	grouped KO genes by gene sets based on the priori knowledge of KEGG database. Subsequently,
177 178	grouped KO genes by gene sets based on the priori knowledge of KEGG database. Subsequently, we randomly shuffled the abundance values of KO genes of a gene set in validation dataset, and
177 178 179	grouped KO genes by gene sets based on the priori knowledge of KEGG database. Subsequently, we randomly shuffled the abundance values of KO genes of a gene set in validation dataset, and performed predictions using the constructed diagnostic model. The decrease of AUC was
177 178 179 180	grouped KO genes by gene sets based on the priori knowledge of KEGG database. Subsequently, we randomly shuffled the abundance values of KO genes of a gene set in validation dataset, and performed predictions using the constructed diagnostic model. The decrease of AUC was considered as the importance of gene set to the diagnostic model. The above procedure was repeated
177 178 179 180 181	grouped KO genes by gene sets based on the priori knowledge of KEGG database. Subsequently, we randomly shuffled the abundance values of KO genes of a gene set in validation dataset, and performed predictions using the constructed diagnostic model. The decrease of AUC was considered as the importance of gene set to the diagnostic model. The above procedure was repeated for 50 times.

183 Evaluation of the model's robustness and generalization

To test the robustness and generalization of selected optimal model among distinct cohorts, we performed cohort-to-cohort transfer and leave-one-cohort-out (LOCO) validation as described in our previous studies [24, 25]. For cohort-to-cohort transfer, diagnostic models were trained on one single cohort and validated on each of the remaining cohorts. For LOCO validation, one single cohort was set as the validation dataset while all other cohorts were pooled together as the discovery dataset.

190

191 Disease specificity assessment of prediction model

- 192 Using non-CD diseases samples of UC, CRC, T2D, LC and PD, we evaluated the disease specificity
- 193 of the predictive model for CD, following the method described by Thomas et al [26]. In detail, we

194 randomly selected 10 control samples and 10 case samples from non-CD external data and added

- 195 them into the control group in the validation dataset. If the model is specific for CD, the model
- 196 would not perform worse with the addition of a case relative to the addition of the controls, because
- 197 the model does not cover the characteristics of non-CD diseases. We repeated the procedure for 50

198 times.

199

200 Validation of microbial genes by qRT-PCR

201 The gDNA was extracted with the TIANamp Stool DNA Kit (Cat# 4992205, TIANGEN) according 202 to the manufacturer's instructions. The primers used for validation are listed in Table S4. To 203 perform the qRT-PCR analysis, the reaction mixture contained the primer pair with concentrations 204 diluted to 0.2 µM and 10 ng gDNA in a 10 µl final volume with the SYBR Green qPCR Mix 205 (Thermo Fisher Scientific). The cycling program was set as indicated: pre-denaturation at 95 °C for 206 10 min; denaturation at 95 °C for 15 s and annealing at 60 °C for 60 s for 40 cycles, followed by 207 melting curve analysis. The qRT-PCR results were quantitated by calculating $-\Delta\Delta$ Ct values 208 between candidate genes and the 16S gene. The significance of the comparison between CD and 209 control samples was tested by a two- sided Wilcoxon rank-sum test (P < 0.05).

211 Statistical analysis

212 Alpha and beta diversity analysis

- 213 Alpha diversity of taxonomic profiles including Shannon, ACE, Simpson and Chao1 index were
- 214 calculated based on Bray-Curtis distance using R (V4.0.5) "vegan" (V2.5.7) package. Beta diversity
- 215 between groups were calculated by permutational multivariate analysis of variance (PERMANOVA)
- 216 called adonis test, and significance was evaluated with 999 permutations.
- 217

218 Co-abundance analysis

219 Firstly, we generated species abundance profiles of CD and controls, respectively. Then we

220 employed SparCC [27] to perform co-abundance analysis of differential multi-kingdom species.

221 Correlations between differential multi-kingdom species were determined with 50 iterations. Then

- 222 SparCC resampled the original dataset through bootstrap method to obtain random datasets. Later,
- 223 pseudo-p-values are calculated from these random data sets to assess the significance of the initial
- 224 observation scores. The statistical significance was calculated with 999 permutations. The network
- 225 was visualized with Gephi (V0.9.5).
- 226

227 Multidimensional signatures association analysis

To further explore the potential associations between multi-dimensional signatures, Hierarchical
All-against-All association testing (HALLA, V 0.8.20) [28] was performed. We generated species-,

- 230 gene-, and SNV-profiles of CD patients and controls, respectively. Subsequently, the associations
- 231 between the species-, gene-, SNV-signatures were calculated in pairs by HALLA. After that, we

- 232 merged the output correlation matrices. Correlations with |cor| > 0.4 and *P*-values < 0.05 were used
- to constructed the network and visualized with Gephi (V0.9.5).
- 234
- 235 **Results**

236 Characterization of multicohort WMS data and study design

- 237 In this study, we collected eight fecal shotgun metagenomics datasets from published studies to
- 238 characterize the gut microbiome in CD patients compared to healthy controls (Fig. 1A). Patients
- treated with antibiotics were excluded. In total, we included 785 samples from CD patients and 456
- 240 healthy control samples across geographically distinct regions from U.S. and China as the discovery
- dataset. In addition, 85 CD samples and 92 controls from three independent cohorts from U.S.,
- 242 Spain and Netherlands were included as the validation dataset. The overall protocol for this study
- 243 (Fig. 1C) was based on the workflow of a previous study [24] with modifications.
- 244

245 Multidimensional alterations in gut microbial profiles in CD patients

- 246 At species level, we found that alpha and beta diversities were significantly differed between CD
- 247 patients and controls (Fig. 2A-B). A total of 80 bacterial species were identified with significantly
- 248 different abundances between CD and control, such as Escherichia coli, Flavonifractor plautii,
- 249 Klebsiella pneumoniae and Bacteroides intestinalis. (Fig. 2C; Table S5). Besides, 147 non-
- 250 bacterial species including 70 fungus, 42 viruses and 35 archaea exhibited differential abundances
- 251 between CD and controls, such as Aspergillus rambellii, Capronia epimyces, Bacteroides phage
- 252 B124-14, Klebsiella virus KpV80 and DPANN group archaeon LC1Nh (Fig. S1 and Table S5).

Further, we investigated the differences in microbial interactions between CD and controls by performing co-abundance analysis via SparCC. Interestingly, interactions among intra-kingdom species were more frequently observed in the network of CD, compared to the network of controls (**Fig. S2**), indicating large scale alterations in the structure and function of the gut microbiome in CD.

259	Next, we assessed the microbial alterations at KO gene level, and identified 497 genes with
260	increased abundance and 1043 genes with decreased abundance in CD patients, such as the genes
261	encoding peptide/nickel transport system permease protein (ABC.PE.P), mannose PTS system EIIC
262	component (manY), flagellin (fliC) and cellobiose PTS system EIIC component (celB) (Fig. 2E;
263	Table S6). For better understanding of these differential KO genes, we performed gene set
264	enrichment analysis (GSEA). 59 enriched pathways, including 18 pathways with increased
265	abundances and 41 with decreased abundances in CD patients, were identified (Fig. S3A and Table
266	S7). Propanoate metabolism, quorum sensing, phosphotransferase system (PTS) and purine
267	metabolism exhibited increased abundances in CD, while biosynthesis of secondary metabolites,
268	pantothenate and CoA biosynthesis exhibited decreased abundances in CD.
269	

For microbial SNV level analysis, a total of 7 commonly observed species that have sufficient coverage (> 3X) in at least 20% of the samples were annotated, with the number of SNVs ranging from 74 with *Bacteroides rodentium* to 99305 with *Bacteroides vulgatus* (Fig. S3B and Fig. S4). A total of 21877 differential SNVs were identified in the seven annotated species (Fig. S3C). For

274	instance, Bacteroides vulgatus, belonging to the most commonly encountered Bacteroides species
275	in the human colon, had 11134 significantly differential SNVs that located on genes such as <i>panC</i> ,
276	<i>rodA</i> and <i>ruvB</i> . (Fig. 2D; Table S8). These differential SNVs are potential candidates of risk factors
277	mediating abnormal gene functions. Collectively, we systemically assessed the multidimensional
278	microbial alterations in CD patients compared to controls, and identified differential signatures for
279	diagnostic model construction.
280	
281	Diagnostic models for CD based on microbial multidimensional signatures
282	Based on all of the differential signatures at species-, gene- and microbial SNV-levels, we

283 constructed models using deep learning algorithm. At species level, we firstly evaluated the 284 capability of single-kingdom species for distinguishing CD from controls. The average AUCs of 285 cross-validation based on fungal, viral, archaeal signatures were 0.89, 0.81 and 0.76, respectively. 286 Compared to non-bacterial species, bacterial species demonstrated a better performance in disease 287 prediction (average AUC=0.94) (Fig. S5A-D). Furthermore, we merged single-kingdom signatures 288 together, and found that the species model based on multi-kingdom signatures had higher diagnostic 289 accuracy with an average AUC of 0.97 (Fig. 3A; Fig. S5E). Interestingly, we noticed that several 290 fungal species including A. rambellii and A. ochraceoroseus were top-ranking features of the model 291 with high SHAP values, suggesting their close association with CD pathology (Fig. S6A and Table 292 **S9**).

294	Subsequently, we constructed a diagnostic model based on 1047 differential KO genes. The gene
295	model achieved an average AUC of 0.95 in 10-fold cross-validation, slightly lower than that of the
296	multi-kingdom species model (Fig. 3A). From feature importance evaluation, we found that CDP-
297	abequose synthase (rfbJ), type VI secretion system protein ImpB (impB), nitrite reductase (NO-
298	forming) (nirK), and celB were the most important KO genes with SHAP values ranged from 0.006
299	to 0.008 (Table S10). Notably, the KO gene <i>celB</i> was found to be significantly increased in CD
300	patients of each dataset (Fig. S6B), suggesting an outstanding contribution of celB gene to the
301	diagnostic power of the model.
302	
303	Furthermore, we explored the diagnostic potentials of microbial SNVs. The SNV model achieved
304	an average AUCs of 0.77 in cross-validation (Fig. 3A). The most important SNVs were mainly from
305	Bacteroides species including B. ovatus, vulgatus and uniformis (Fig. S7A and Table S11). As the
306	most widely colonized microbes in the gut [29], Bacteroides species contributes to the major
307	diagnostic power of the SNV model in our results.
308	
309	Finally, we constructed a model with the combination of species-, gene- and SNV-signatures (Fig.
310	S8D). The combined model achieved an average AUC of 0.95. Interestingly, the performance of
311	combined model was not significantly improved compared to species- and gene- models, and most
312	of the top-ranking features were from KO genes (Fig. 3A; Fig. S7B). These results suggest that the

- 313 gene signatures are the most powerful biomarkers for CD.
- 314

315 Gene model achieves superior robustness and generalization

316	To assessed the robustness and generalization of species-, gene-, SNV- and combined models, we
317	performed internal and external validations. With the internal validation cohorts, the gene model
318	achieved the highest average AUCs of 0.87 and 0.89 in cohort-to-cohort transfer and LOCO
319	validation, respectively (Fig. 3C-D), compared to other diagnostic models (Fig. S9A-G). In external
320	validation, the gene model also exhibited the best performance with an average AUC of 0.91 in
321	three independent cohorts (Fig. 3B). Taken together, the gene model demonstrated superior
322	robustness compared to the species-, SNV-model and even the combined model.
323	
324	Gene model is highly specific for CD
325	To ascertain the discriminative power of the gene model, that is, the model is specific for CD but
326	not other microbiome-related diseases, we chose five microbiome-related diseases including UC,
327	CRC, PD, T2D and LC to evaluate the disease specificity of the gene model. Adding UC samples
328	into three independent validation cohorts decreased the AUC by 6.6, 10.1 and 12.9%, respectively
329	(Fig. 3E). These changes were not significant considering the baseline values of the altered AUCs
330	when adding CD samples in the validation dataset (decreased AUCs by 10.7, 17.5 and 20.5%,
331	respectively, Fig. S9H). With CRC cohorts, slight and insignificant changes of AUCs in validation
332	(decreased by 0.7, 1.1 and 1.3%, respectively) were observed. Similarly, slight and insignificant
333	changes of AUC were observed in validations with T2D (increased by 2.0, 3.4 and 4.0%,
334	respectively), liver cirrhosis (increased by 1.5, 2.5 and 3.0%, respectively) and PD (increased by
335	1.6, 2.6 and 3.1%, respectively). Altogether, the slight changes in AUCs suggest limited effects of

the samples with non-CD diseases on the CD model, indicating that our diagnostic model is specific

337 for CD.

338

339 Outstanding contributions of phosphotransferase system to the diagnostic capability of the

340 gene model

341 To evaluate the respective contributions of each gene set and of key gene feature in the gene model, 342 the KO gene features were grouped by gene set and the importance of each gene set was evaluated 343 as described in Methods section. Relative to the baseline AUC of 0.91, the abundance disturbance 344 of the gene sets quorum sensing, PTS and ABC transporters caused the greatest decrease of AUC 345 in the predictive model by 1.09 to 1.70 percent (Fig. 4A). Further, we performed recursive feature 346 elimination by gene sets and reconstructed diagnostic models. We found that the AUC of cross-347 validation did not decrease significantly until the glycerolipid metabolism gene set was eliminated, 348 which confirmed the important contribution of quorum sensing, PTS, ABC transporters, fructose 349 and mannose metabolism and glycerolipid metabolism to the diagnostic model (Fig. S10A). To 350 further strengthen these results, we constructed a sub-model with genes of these five gene sets, 351 which achieved an AUC of 0.89 in cross-validation (Fig. S10B). The sub-model displayed decent 352 robustness in internal validations and achieved an average AUC of 0.81 in external validation (Fig. 353 **S10C**). Notably, we found that *celB* was the most important feature in the sub-model (Table S12). 354 These results suggest that the above identified gene sets are the key contributors to diagnostic 355 capabilities of the gene model.

357	Next, we assessed the prediction power of representative KO genes of each gene set (Table S13).
358	Notably, <i>celB</i> and <i>manY</i> displayed excellent diagnostic capabilities with AUCs of 0.74 and 0.71,
359	respectively (Fig. 4B). Since <i>celB and manY</i> (also a member of fructose and mannose metabolism)
360	are both members of PTS, the above results indicate that PTS gene set mediated the most significant
361	functional alterations of gut microbiome in CD patients. Finally, we validated the abundances of
362	celB and manY with an independent cohort of CD patients and controls by qRT-PCR. Consistent
363	with the metagenomic data (Fig. 4C), both <i>celB</i> and <i>manY</i> were significantly more abundant in CD
364	patients (Fig. 4D). Additionally, we validated the abundances of those genes that belong to
365	important pathways and with high feature importance by qRT-PCR (Fig. S11). These results
366	revealed the respective contributions of individual gene feature to the diagnostic capability of the
367	gene model, and identified <i>celB</i> and <i>manY</i> as the individual biomarkers with the highest predictive
368	power for diagnosing CD.

369

370 Altered interactions within and between each level of microbial signatures in CD

For a global understanding of the interactions among all the microbial signatures in CD, we investigated the associations among all the microbial signatures via HALLA (**Fig. 5A-B**). In both CD and control networks, considerable associations were observed between KO genes and species, but few observed between SNVs and the other two levels (|correlation| > 0.4) (**Fig. 5B, E**). More associations were observed in the network of CD (206 associations) (**Fig. 5D**), than in the network of controls (163 associations) (**Fig. 5G; Table S14-15**). Interestingly, there were more negative associations between the gene- and the species-signatures in the control network than that in the CD

378	network. For example, D-nopaline dehydrogenase (nos), type IV secretion system protein TrbJ (trbJ)
379	genes were negatively associated with R. hominis, R. bassiana, and C. aerofaciens. Notably, we
380	found that KO genes had stronger degree centrality than species in the CD network (Fig. 5C).
381	Moreover, compared to the control network, these KO genes in CD tended to form isolated clusters,
382	as exemplified by the independent module consisting <i>celB</i> and <i>manY</i> in the CD network (Fig. 5A).
383	
384	Discussion
385	Here, for the first time, multidimensional microbial signatures of CD were systematically analyzed
386	with multiple cohorts of distinct cultural and geographical backgrounds. In comparison of the
387	diagnostic capabilities of the microbial signatures including differential species, genes and SNVs,
388	the gene model achieved superior accuracy and robustness in distinguishing CD from controls, and
389	the gene model was specific for CD against other microbiome-related diseases. Finally, the major
390	contributing genes in the gene model were identified and validated.
391	
392	The multidimensional alterations of the gut microbiome in CD patients contain massive
393	information that could predict the disease state. Therefore, we employed deep learning method to
394	fit the underlying characteristics of gut microbiome in CD. With the microbial species models, while
395	bacterial species achieved the best performance among single-kingdom models, multi-kingdom
396	model with both bacteria and non-bacterial species achieved better accuracy than the single-
397	kingdom models, which is similar to our observations with the microbial models for colorectal
398	cancer [14].

399	Comparing models of three different types, the gene model demonstrated the best generalization
400	and robustness in model evaluations compared to the species-, SNV- and combined models. This is
401	reasonable, considering that the homologous genes of different microorganisms may contribute to
402	the same abnormalities in the gut microbiome in connection to specific pathological processes [30,
403	31].
404	
405	In examining the contributions of individual gene set and gene to the diagnostic capabilities of
406	the gene model, we found that genes that belong to PTS gene set had great impacts on the model
407	accuracy in abundance disturbance analysis. The importance of the PTS gene set in the diagnosis

408 model was also demonstrated in recursive feature elimination analysis and in cross-validation of the

409 sub-model. In gut bacteria, the PTS is known as a system that catalyze sugar transport as well as

410 sugar phosphorylation [32, 33]. In addition, the PTS regulates a wide variety of transport, metabolic

411 processes, biofilm formation and virulence [34], thus it is considered as a comprehensive regulation

412 and coordination system. We observed that the CD patients exhibited increased abundance in PTS ,

413 and that the KO genes in PTS were associated with the differential species in CD (Fig. S12A), such

414 as *Streptococcus pneumoniae* and *A. ochraceoroseus* that are associated with gut diseases [35-37].

415 That is, PTS may participate in the pathogenesis of CD.

More importantly, the KO gene *celB* that encodes the enzyme IIC component (EIIC) of cellobiose PTS, exhibited the top-ranking predictability among all the gene markers and an increased abundance in CD patients. These observations support an outstanding potential for the microbial gene *celB* of PTS to be used as a biomarker for non-invasive CD diagnosis. Moreover, *celB* was

420	associated with K. pneumonia (Fig. S12B), which is in line with the roles of celB component of
421	PTS in biofilm formation and the virulence of K. pneumoniae [38], and the roles of K. pneumoniae
422	in the initiation and perpetuation of the pathological damage of CD were also demonstrated [39].
423	We also observed a significant increase of K. pneumoniae in CD patients (Fig. S12C and Table
424	S5). Therefore, it is reasonable to hypothesize that the interaction between <i>celB</i> and <i>K</i> . <i>pneumoniae</i>
425	may contribute to the development of CD.
426	Another microbial gene manY was also identified as a biomarker for CD diagnosis. manY encodes
427	the EIIC component of mannose PTS system (man-PTS) that is a part of the PTS regulatory network.
428	The hairpin tips of IIC in man-PTS is coordinated with mannose and mediates the mannose transport
429	[40]. Interestingly, previous studies found that man-PTS and cellobiose-PTS were upregulated in
430	gut microbes by changing from a low-fat diet to a high-fat, high-sugar diet [40, 41], suggesting that
431	the PTS of gut microbes is sensitive to the nutritional environment of mucosal surfaces. Thus, the
432	up-regulations of <i>celB</i> and <i>manY</i> in CD likely indicate the up-regulation in the biological activities
433	of cellobiose-PTS and man-PTS in association with CD pathology. That is, manY may also
434	participate in the pathogenesis of CD. However, the cause of these alterations in CD is not clear and
435	requires further investigation.
436	
40 5	

437 Our work takes advantages of excellent adaptability and learning ability of AI in large dataset
438 and provides an effective non-invasive diagnostic tool with improved discrimination power for CD.
439 However, the interpretability of the AI model is limited, which could be improved with a causal
440 analysis in the future.

441

442 **Conclusions**

- 443 Our global metagenomic analysis unravels the multidimensional alterations of the microbial
- 444 communities in CD and identifies microbial genes as robust diagnostic biomarkers across cohorts.
- 445 These genes are functionally related to the pathogenesis of CD. Future study on these genes may
- 446 lead to an effective non-invasive diagnostic tool for CD.
- 447

448 Ethics approval and consent to participate

- 449 All participants provided written informed consent prior to data collection. The study was approved
- 450 by the Institutional Review Board at the Shanghai Tenth People's Hospital, Tongji University,
- 451 Shanghai (No. 20KT863).
- 452

453 **Consent for publication**

- 454 Not applicable.
- 455

456 Availability of data and materials

- 457 The data that support the findings of this study are available from the corresponding author, upon
- 458 reasonable request. The code and scripts are available on GitHub
- 459 (https://github.com/tjcadd2020/Diagnosis-for-CD).
- 460

461 **Competing interests**

462 The authors declare that they have no competing interests.

463

464 Authors' contributions

- 465 LZ, ZL, QH and RZ conceived and designed the project. SG and XG drafted the manuscript. RZ,
- 466 DW, ZF, NJ, RS, WG, QH, ZL and LZ revised the manuscript. All authors read and approved the
- 467 final manuscript.

468

469 Acknowledgements

- 470 This work was supported by the National Natural Science Foundation of China (82170542 to RZ,
- 471 92251307 to RZ, 32200529 to DW, 82000536 to NJ), the National Key Research and Development

472 Program of China (2021YFF0703700/2021YFF0703702 to RZ), and Guangdong Province "Pearl

- 473 River Talent Plan" Innovation and Entrepreneurship Team Project (2019ZT08Y464 to LZ). The
- 474 funders had no role in study design, data collection and analysis, decision to publish, or preparation
- 475 of the manuscript.

476

477 Abbreviations

478 **ABC.PE.P**: peptide/nickel transport system permease protein; **agaF**: N-acetylgalactosamine PTS

479 system EIIA component; AKR1A1: alcohol dehydrogenase (NADP+); ALDH: aldehyde

480 dehydrogenase (NAD+); allA: ureidoglycolate lyase; AUC: area under the ROC curve; CD:

- 481 Crohn's disease; celB: cellobiose PTS system EIIC component; CRC: colorectal cancer; EIIC:
- 482 enzyme IIC component; ENA: European Nucleotide Archive; fliC: flagellin; FNN: Feedforward
- 483 neural network; **GSEA**: gene set enrichment analysis; **IBD**: inflammatory bowel disease; **impB**:

484	type VI secretion system protein ImpB; KO: KEGG Orthology; LC: liver cirrhosis; LOCO: leave-
485	one-cohort-out; maeB: malate dehydrogenase (oxaloacetate-decarboxylating) (NADP+); manY:
486	mannose PTS system EIIC component; nirK: nitrite reductase (NO-forming); pckA:
487	phosphoenolpyruvate carboxykinase (GTP); PD: Parkinson's disease; PTS: phosphotransferase
488	system; ReLU: rectified linear unit; rfbJ: CDP-abequose synthase; ROC: receiver operating
489	characteristic; SHAP: SHapley Additive exPlanations; SNVs: single nucleotide variants; sucD:
490	succinyl-CoA synthetase alpha subunit; T2D: type-2 diabetes; tcPp: toxin coregulated pilus
491	biosynthesis protein P; tmoC: toluene monooxygenase system ferredoxin subunit; trbJ: type IV
492	secretion system protein TrbJ; ttuC: artrate dehydrogenase/decarboxylase / D-malate
493	dehydrogenase; UC: ulcerative colitis; WMS: whole metagenome sequencing

494

495 **References**

- 496 1. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence
- 497 and prevalence of inflammatory bowel disease in the 21st century: a systematic review of
- 498 population-based studies. Lancet. 2017;390(10114):2769-78.

499 2. The global, regional, and national burden of inflammatory bowel disease in 195 countries and

- 500 territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet
- 501 Gastroenterol Hepatol. 2020;5(1):17-30.
- 502 3. Feuerstein JD, Cheifetz AS. Crohn Disease: Epidemiology, Diagnosis, and Management.
- 503 Mayo Clin Proc. 2017;92(7):1088-103.

- 4. Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, et al. ECCO-ESGAR
- 505 Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD,
- 506 detection of complications. J Crohns Colitis. 2019;13(2):144-64.
- 507 5. Feld LD, Kirk K, Feld AD. A High Quality Approach to Addressing Complications of
- 508 Endoscopy and Optimizing Risk Management Strategies. Techniques and Innovations in
- 509 Gastrointestinal Endoscopy. 2022.
- 510 6. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel
- 511 disease. Gastroenterology. 2011;140(6):1817-26 e2.
- 512 7. Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, et al. C-Reactive Protein,
- 513 Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic
- 514 Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am J
- 515 Gastroenterol. 2015;110(6):802-19; quiz 20.
- 516 8. Dubinsky M, Braun J. Diagnostic and Prognostic Microbial Biomarkers in Inflammatory
- 517 Bowel Diseases. Gastroenterology. 2015;149(5):1265-74.e3.
- 518 9. Lloyd-Price J, Arze C, Ananthakrishnan AN, Schirmer M, Avila-Pacheco J, Poon TW, et al.
- 519 Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature.
 520 2019;569(7758):655-62.
- 521 10. Huang Q, Zhang X, Hu Z. Application of Artificial Intelligence Modeling Technology Based
- 522 on Multi-Omics in Noninvasive Diagnosis of Inflammatory Bowel Disease. J Inflamm Res.
- 523 2021;14:1933-43.

- 524 11. Pascal V, Pozuelo M, Borruel N, Casellas F, Campos D, Santiago A, et al. A microbial
- 525 signature for Crohn's disease. Gut. 2017;66(5):813-22.
- 526 12. Franzosa EA, Sirota-Madi A, Avila-Pacheco J, Fornelos N, Haiser HJ, Reinker S, et al. Gut
- 527 microbiome structure and metabolic activity in inflammatory bowel disease. Nat Microbiol.
- 528 2019;4(2):293-305.
- 529 13. Tierney BT, Tan Y, Kostic AD, Patel CJ. Gene-level metagenomic architectures across
- 530 diseases yield high-resolution microbiome diagnostic indicators. Nat Commun. 2021;12(1):2907.
- 531 14. Liu NN, Jiao N, Tan JC, Wang Z, Wu D, Wang AJ, et al. Multi-kingdom microbiota analyses
- 532 identify bacterial-fungal interactions and biomarkers of colorectal cancer across cohorts. Nat
- 533 Microbiol. 2022;7(2):238-50.
- 534 15. Yan Y, Nguyen LH, Franzosa EA, Huttenhower C. Strain-level epidemiology of microbial
- 535 communities and the human microbiome. Genome Med. 2020;12(1):71.
- 536 16. Ma C, Chen K, Wang Y, Cen C, Zhai Q, Zhang J. Establishing a novel colorectal cancer
- 537 predictive model based on unique gut microbial single nucleotide variant markers. Gut Microbes.
- 538 2021;13(1):1-6.
- 539 17. Jiang S, Chen D, Ma C, Liu H, Huang S, Zhang J. Establishing a novel inflammatory bowel
- 540 disease prediction model based on gene markers identified from single nucleotide variants of the
- 541 intestinal microbiota. iMeta. 2022;1(3).
- 542 18. Wood DE, Lu J, Langmead B. Improved metagenomic analysis with Kraken 2. Genome Biol.
- 543 2019;20(1):257.

- 544 19. Li D, Liu C-M, Luo R, Sadakane K, Lam T-W. MEGAHIT: an ultra-fast single-node solution
- 545 for large and complex metagenomics assembly via succinct de Bruijn graph. Bioinformatics.
- 546 2015;31(10):1674-6.
- 547 20. Hyatt D, Chen G-L, LoCascio PF, Land ML, Larimer FW, Hauser LJ. Prodigal: prokaryotic
- 548 gene recognition and translation initiation site identification. BMC Bioinformatics. 2010;11(1):119.
- 549 21. Fu L, Niu B, Zhu Z, Wu S, Li W. CD-HIT: accelerated for clustering the next-generation
- 550 sequencing data. Bioinformatics. 2012;28(23):3150-2.
- 551 22. Nayfach S, Rodriguez-Mueller B, Garud N, Pollard KS. An integrated metagenomics pipeline
- 552 for strain profiling reveals novel patterns of bacterial transmission and biogeography. Genome Res.
- 553 2016;26(11):1612-25.
- 23. Scott M. Lundberg S-IL. A Unified Approach to Interpreting Model Predictions. NIPS'17:
- 555 Proceedings of the 31st International Conference on Neural Information Processing Systems.
- 556 2017:4768-77.
- 557 24. Gao W, Chen W, Yin W, Zhu X, Gao S, Liu L, et al. Identication and validation of microbial
- 558 biomarkersfrom cross-cohort datasets using xMarkerFinder. Protocol Exchange. 2022.
- 559 25. Wu Y, Jiao N, Zhu R, Zhang Y, Wu D, Wang AJ, et al. Identification of microbial markers
- across populations in early detection of colorectal cancer. Nat Commun. 2021;12(1):3063.
- 561 26. Thomas AM, Manghi P, Asnicar F, Pasolli E, Armanini F, Zolfo M, et al. Metagenomic
- 562 analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a
- 563 link with choline degradation. Nat Med. 2019;25(4):667-78.

- 564 27. Friedman J, Alm EJ. Inferring Correlation Networks from Genomic Survey Data. PLOS
- 565 Computational Biology. 2012;8(9):e1002687.
- 566 28. Ghazi AR, Sucipto K, Rahnavard G, Franzosa EA, McIver LJ, Lloyd-Price J, et al. High-
- 567 sensitivity pattern discovery in large, paired multi-omic datasets. bioRxiv. 2021:2021.11.11.468183.
- 568 29. Kim S, Covington A, Pamer EG. The intestinal microbiota: Antibiotics, colonization resistance,
- and enteric pathogens. Immunol Rev. 2017;279(1):90-105.
- 570 30. Schirmer M, Garner A, Vlamakis H, Xavier RJ. Microbial genes and pathways
- 571 in inflammatory bowel disease. Nat Rev Microbiol. 2019;17(8):497-511.
- 572 31. Rowland I, Gibson G, Heinken A, Scott K, Swann J, Thiele I, et al. Gut microbiota functions:
- 573 metabolism of nutrients and other food components. Eur J Nutr. 2018;57(1):1-24.
- 574 32. Lengeler JW, Jahreis K. Bacterial PEP-dependent carbohydrate: phosphotransferase systems
- 575 couple sensing and global control mechanisms. Contrib Microbiol. 2009;16:65-87.
- 576 33. Västermark A, Saier MH, Jr. The involvement of transport proteins in transcriptional and
- 577 metabolic regulation. Curr Opin Microbiol. 2014;18:8-15.
- 578 34. Saier MH, Jr. The Bacterial Phosphotransferase System: New Frontiers 50 Years after Its
- 579 Discovery. J Mol Microbiol Biotechnol. 2015;25(2-3):73-8.
- 580 35. Aymeric L, Donnadieu F, Mulet C, du Merle L, Nigro G, Saffarian A, et al. Colorectal cancer
- 581 specific conditions promote Streptococcus gallolyticus gut colonization. Proc Natl Acad Sci U S A.
- 582 2018;115(2):E283-e91.

- 583 36. Lin Y, Lau HC, Liu Y, Kang X, Wang Y, Ting NL, et al. Altered Mycobiota Signatures and
- 584 Enriched Pathogenic Aspergillus rambellii Are Associated With Colorectal Cancer Based on
- 585 Multicohort Fecal Metagenomic Analyses. Gastroenterology. 2022;163(4):908-21.
- 586 37. Coker OO, Nakatsu G, Dai RZ, Wu WKK, Wong SH, Ng SC, et al. Enteric fungal microbiota
- 587 dysbiosis and ecological alterations in colorectal cancer. Gut. 2019;68(4):654-62.
- 588 38. Wu M-C, Chen Y-C, Lin T-L, Hsieh P-F, Wang J-T, Camilli A. Cellobiose-Specific
- 589 Phosphotransferase System of Klebsiella pneumoniae and Its Importance in Biofilm Formation and
- 590 Virulence. Infection and Immunity. 2012;80(7):2464-72.
- 591 39. Rashid T, Ebringer A, Wilson C. The role of Klebsiella in Crohn's disease with a potential for
- the use of antimicrobial measures. Int J Rheumatol. 2013;2013:610393.
- 593 40. Jeckelmann JM, Erni B. The mannose phosphotransferase system (Man-PTS) Mannose
- transporter and receptor for bacteriocins and bacteriophages. Biochim Biophys Acta Biomembr.
- 595 2020;1862(11):183412.
- 596 41. Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. The effect of diet on the
- 597 human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med.
- 598 2009;1(6):6ra14.
- 599

600 Figure Legends

601

Fig. 1. Overview of the fecal samples included in this study and the analysis protocol. A We
collected a total of 1418 samples from 8 cohorts with fecal shotgun metagenomic data. The
discovery dataset included D1, D2, D3, D4 and D5. The validation dataset included V1, V2 and V3.

605	B Three levels of analysis were conducted in this study: species-, gene- and microbial SNV- levels.
606	C The overall workflow of the study: Firstly, the microbial alterations were identified to retrieve
607	the differential multidimensional signatures of gut microbiome. Subsequently, diagnostic models
608	were constructed and the optimal model was selected according to the performances of the models
609	in internal and external validations. Finally, disease specificity of model was evaluated and model
610	interpretation was conducted for final determination of the microbial biomarker, and then
611	biomarkers were validated by qRT-PCR analysis.
612	
613	
614	Fig. 2. Multidimensional alterations in the gut microbiome of CD patients at species-, gene-
615	and SNV-levels. A Alpha diversity measured by Shannon, ACE, Simpson and Chaol index of
616	patients with CD (orange, n = 785) and control individuals (blue, n = 456); * $P < 0.05$, ** $P < 0.01$,
617	*** $P < 0.001$ and **** $P < 0.0001$. B Principal coordinate analysis (PCoA) of samples from all five

618 cohorts based on Bray-Curtis distance, which shows that microbial compositions were different

between groups ($R^2 = 0.0265$, P = 0.001). P values of beta diversity based on Bray–Curtis distance

620 were calculated with PERMANOVA by 999 permutations (two-sided test). C Phylogenetic tree

621 showing the differential bacteria species, grouped by the phyla. The differential species in each

622 dataset are shown in each circle 'D1-D5' ($P \le 0.05$, two-sided test); the meta-analysis results in

623 integrated dataset were marked by 'All'. Increased and decreased abundances are indicated by red

624 and blue, respectively. **D** The chord diagram shows the distributions of annotated SNVs in

625 Bacteroides vulgatus genome. The outer circle represents the genome of B. vulgatus; the inner

626	circles represent the GC-content (cyan indigo lines), sequencing depth (purple lines) and sites of
627	differential SNVs (brown points) in the genome, respectively. E UpSet plot showing the number of
628	differential KO genes identified via MaAsLin2 in each dataset and those shared by the datasets.
629	The number above each column represents the intersection size of differential KO genes. The
630	connected dots represent the common differential genes across connected cohorts. The set size on
631	the right represents the number of differential genes in each cohort.

632

633 Fig. 3. The performance of diagnostic models constructed with multidimensional signatures.

634 A The ROC curves from ten-fold cross-validation of species-, gene-, SNV- and combined diagnostic 635 models. B The AUCs of species-, gene-, SNV- and combined diagnostic models in external 636 validation dataset. C The AUCs of each model in cohort-to-cohort validation. Each number 637 represents the average AUC of validation with the cohort specified by its column tag as the training 638 cohort, and all other cohorts as the validation cohorts. D The AUC of each model in LOCO 639 validation. Each number represents the resulting AUC of validation with the cohort specified by its 640 column tag as the validation cohort while the other cohorts combined as training cohort. E 641 Prediction performances as AUC values on the validation cohorts when adding an external set of 642 control and case samples from non-CD disease cohorts (ulcerative colitis (UC), colorectal cancer 643 (CRC), type-2 diabetes (T2D), liver cirrhosis (LC) and Parkinson's disease (PD)). Gray and colored 644 bars are the AUCs after adding control and case samples from the non-CD disease cohorts, 645 respectively.

647	Fig. 4. The model interpretation of the gene model. A The left column lists the average percent
648	change of AUC after shuffling the abundance values of the genes in each gene set in validation
649	dataset with the background color indicating the degrees of AUC change; the center left column
650	lists the number of KO genes in each gene set with the background color indicating the set size; the
651	center right column is the representative signature of each gene set; and the right column lists the
652	cross-validation AUC of the representative microbial gene with the background color indicating an
653	increased (red) or decreased (blue) AUC. The line plot shows the values of feature importance of
654	the representative signatures (upper horizontal axis); the box plot shows the AUCs of each gene set
655	in validation dataset with the dotted line representing the baseline AUC of 0.91 (lower horizontal
656	axis). B The ROC curve shows diagnostic performance of microbial gene celB and manY,
657	respectively. C-D The box plot shows the abundances of $celB$ (upper) and $manY$ (lower) in
658	metagenomic data (C) and qRT-PCR data (D) (N=37, CD; N=36, control), respectively. Data are
659	presented as mean \pm standard deviation. * <i>P</i> < 0.05, ** <i>P</i> < 0.01, *** <i>P</i> < 0.001 and **** <i>P</i> < 0.0001.
660	
661	Fig. 5. The cross-talk between multidimensional signatures. A-B Correlations among species-,
662	gene- and SNV- signatures in the control (A) and the CD (B) networks. The colors of nodes indicate

663 signatures of different levels: species (green), KO genes (yellow), and SNVs (brown). Red line

664 indicates positive interaction; and blue line indicates negative interaction (|correlation|>0.4, FDR <

665 0.05). C Density distribution of correlations between different levels of signatures (FDR < 0.05) in

666 the control network. D Density distribution of node degrees for different levels of signatures

667 ((|correlation|>0.4, FDR < 0.05) in the control network. E Numbers of edges (|correlation|>0.4, FDR

- 668 < 0.05) in the control network. F Density distribution of correlations between different levels of
- 669 signatures (FDR < 0.05) in the CD network. G Density distribution of node degrees for different
- 670 levels of signatures ((|correlation|>0.4, FDR < 0.05) in the CD network. H Number of edges
- 671 (|correlation|>0.4, FDR < 0.05) in the CD network.

Δ		Dataset	CD	Control	Country	В	
		D1	248	322	U.S.	Species	
	ح	D2	89	21	U.S.	-	
	cove tasel	D3	<mark>68</mark>	34	U.S.		and the second se
	Disc da	D4	340	26	U.S.	Gene	ž
		D5	40	53	China (in-house)		- Andrew Andre
	E T	V1	44	49	U.S.		
39	latic aset	V2	21	23	Spain		Ż
	Valic dat	V3	20	20	Nether lands	SNV	S.









